Skip to content
ClinCalc Pro
Menu
Direct vasodilator

Hydralazine hydrochloride

Brand names: Apresoline

Used in: Pre-eclampsia & Obstetric Emergencies

Hydralazine hydrochloride is a directly acting arterial vasodilator used for hypertension (including hypertensive emergencies and in pregnancy by injection) and, combined with a nitrate, as an option in heart failure.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It relaxes arteriolar smooth muscle to reduce systemic vascular resistance and afterload; the resulting fall in blood pressure can trigger reflex tachycardia and fluid retention.

Prescribing in practice

  • Long-term use, particularly at higher doses or in slow acetylators, can cause a drug-induced lupus-like syndrome, so persistent arthralgia, rash or systemic symptoms should prompt review.
  • Reflex tachycardia and sodium and water retention often necessitate co-prescription of a beta-blocker and a diuretic.
  • It can precipitate or worsen angina and should be used with caution in coronary artery disease.

Monitoring

Monitor blood pressure and heart rate, with review for lupus-like symptoms (and antinuclear antibodies if suspected) during prolonged therapy.

Counselling the patient

  • Report persistent joint pain, unexplained fever or a facial rash.
  • Palpitations and headache can occur as your body adjusts.
  • Rise slowly from sitting or lying to reduce dizziness.

Evidence & guidelines

The combination of hydralazine with a nitrate is supported in heart failure, notably in the A-HeFT trial in self-identified Black patients.

Reference: NICE NG133; ESC guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.